<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04794465</url>
  </required_header>
  <id_info>
    <org_study_id>2021/5006</org_study_id>
    <nct_id>NCT04794465</nct_id>
  </id_info>
  <brief_title>Asymptomatic Inflammatory Bowel Disease in Catalonia</brief_title>
  <official_title>Asymptomatic Inflammatory Bowel Disease Diagnosed During the Colorectal Cancer Population Screening un Catalonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corporacion Parc Tauli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corporacion Parc Tauli</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An early treatment of inflammatory bowel disease (IBD) has been proposed to correlate to&#xD;
      better outcomes. In Catalonia the screening programme was implemented in all the territory in&#xD;
      2015. The aim of this study is to describe the natural history of the asymptomatic IBD&#xD;
      detected during colorectal cancer population screening.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be performed and reported according to the STROBE Statement guidelines (&#xD;
      http://www.strobe-statement.org/index.php?id=strobe-home).&#xD;
&#xD;
      Design:&#xD;
&#xD;
      Observational, multicentre and retrospective cohort study.&#xD;
&#xD;
      Centre selection and recruitment:&#xD;
&#xD;
      All the participating centres in population colorectal cancer screening in Catalonia will be&#xD;
      invited. All the participating centres must certify the approval of the protocol in their&#xD;
      ethical committees.&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      All patients with asymptomatic IBD diagnosed during the population colorectal cancer&#xD;
      screening in the Catalonian colorectal screening program within the period 2000 to 2019 will&#xD;
      be included.&#xD;
&#xD;
      Study variables&#xD;
&#xD;
      Prevalence of asymptomatic IBD diagnosed and their evolution through the years will be&#xD;
      described. The following variables will be collected (annex1):&#xD;
&#xD;
        -  Sex (male, female)&#xD;
&#xD;
        -  Age&#xD;
&#xD;
        -  Fecal immunotest (value)&#xD;
&#xD;
        -  Date of screening colonoscopy (yyyy/mm/dd)&#xD;
&#xD;
        -  Ileoscopy performed (yes/no)&#xD;
&#xD;
        -  Type of IBD (CD, UC, indeterminate colitis)&#xD;
&#xD;
        -  Endoscopic findings: mild-moderate activity or severe activity for CD and Mayo score for&#xD;
           UC (value of the scores).&#xD;
&#xD;
        -  Montreal classification (value of the classification)&#xD;
&#xD;
        -  Histology (diagnostic, compatible, unspecific or no compatible)&#xD;
&#xD;
        -  Microscopic description (cryptitis, abscess, mucus depletion, granuloma, architectural&#xD;
           pattern alteration&#xD;
&#xD;
        -  Past medical history, smoking habit, previous abdominal surgeries and comorbidities.&#xD;
&#xD;
        -  Familiar history of IBD&#xD;
&#xD;
        -  Extraintestinal manifestations (cutaneous, ophthalmologic, articular)&#xD;
&#xD;
        -  Other studies performed (endoscopic capsule, MRI, gastroscopy, echography).&#xD;
&#xD;
        -  Calprotectin: value of the first analysis in the outpatient visit.&#xD;
&#xD;
        -  Blood test: Haemoglobin, ferritin and PCR: values of the first analysis in the&#xD;
           outpatient visit.&#xD;
&#xD;
        -  Fist symptom: none, change in depositional rhythm, abdominal pain, weight loss, rectal&#xD;
           urgency, anal pain, iron deficiency anaemia.&#xD;
&#xD;
        -  Date of first IBD symptom (yyyy/mm/dd)&#xD;
&#xD;
        -  Time to first IBD symptom: time in days from the diagnosis of IBD.&#xD;
&#xD;
        -  Treatments used: none; 5- aminosalicylates, corticosteroids, non-biologic&#xD;
           immunosuppressive treatment, biologic treatment, surgery&#xD;
&#xD;
        -  Treatment start and end date (yyyy/mm/dd)&#xD;
&#xD;
        -  Time to first treatment: time in days from the diagnosis of IBD.&#xD;
&#xD;
        -  Follow-up endoscopy: Date (yyyy/mm/dd) and activity.&#xD;
&#xD;
      Data collection:&#xD;
&#xD;
      All patients with asymptomatic IBD diagnosed during the population colorectal cancer&#xD;
      screening within the period 2000 to 2019 will be identified by the colorectal cancer&#xD;
      screening program registry.&#xD;
&#xD;
      Patient identity will be given to a data manager. This manager will administrate the data of&#xD;
      each patient in their hospital.&#xD;
&#xD;
      The person in charge of the study in each hospital will collect the anonymized data using&#xD;
      REDCap database (Research Electronic Data Capture), a secure, web-based application designed&#xD;
      to support data collection form research studies.&#xD;
&#xD;
      Statistical methods:&#xD;
&#xD;
      Categorical variable will be given as natural frequencies and percentages and quantitative&#xD;
      variables will be given as mean or median and standard deviation or interquartile ranges.&#xD;
      Kaplan-Meier analysis will be used to describe the time to first symptom and or time to first&#xD;
      treatment. If necessary, the long rank test will be used to compare survival curves. A&#xD;
      multivariate Cox analysis will be performed to ascertain the independent predictors of&#xD;
      aggressive disease.&#xD;
&#xD;
      Ethical issues:&#xD;
&#xD;
      The research will use retrospective anonymized data from the technical screening office of&#xD;
      Catalonia. No personal data will be used, and all the patient data will be encrypted, so that&#xD;
      no personal identification would be retrievable or traceable to the original source from the&#xD;
      working database.&#xD;
&#xD;
      All the researchers who collaborate in the study will sign a commitment document in which&#xD;
      their functions and obligations will be defined. Both in the collection of data and in the&#xD;
      analysis, Organic Law 3/2018, of December 5, on the Protection of Personal Data and guarantee&#xD;
      of digital rights and the provisions of European Regulation 679/2016 will be followed.&#xD;
&#xD;
      The study was revised and approved by the local ethics committee of the Hospital&#xD;
      universitarian Parc Tauli in Sabadell (CEIC 2021/5006) on 15 February 2021. The study will&#xD;
      comply with the ethical guidelines of the Declaration of Helsinki. Therefore, as the study&#xD;
      uses retrospective anonymized data and it has no impact on evolution or treatment patient,&#xD;
      there is no need to obtain informed consent. The study will be performed in accordance with&#xD;
      the STROBE statement for reporting observational studies in Epidemiology.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>15 Years</target_duration>
  <primary_outcome>
    <measure>Time to treatment</measure>
    <time_frame>From date of diagnosis until the date of first treatment, assessed up to 19 years.</time_frame>
    <description>To see the evolution of the asymptomatic IBD and the need for the treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to symptoms</measure>
    <time_frame>From date of diagnosis until the date of first symptom, assessed up to 19 years.</time_frame>
    <description>To see the evolution of the asymptomatic IBD and the symptomatology</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <arm_group>
    <arm_group_label>Asymptomatic IBD diagnosed during the colorectal cancer screening</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Colorectal cancer screening</intervention_name>
    <description>Patients with IBP diagnosed during the colorectal cancer screening</description>
    <arm_group_label>Asymptomatic IBD diagnosed during the colorectal cancer screening</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Centre selection and recruitment:&#xD;
&#xD;
        All the participating centres in population colorectal cancer screening in Catalonia will&#xD;
        be invited. All the participating centres must certify the approval of the protocol in&#xD;
        their ethical committees.&#xD;
&#xD;
        Study population:&#xD;
&#xD;
        All patients with asymptomatic IBD diagnosed during the population colorectal cancer&#xD;
        screening in the Catalonian colorectal screening program within the period 2000 to 2019&#xD;
        will be included.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients with asymptomatic IBD diagnosed during the population colorectal cancer&#xD;
             screening in the Catalonian colorectal screening program within the period 2000 to&#xD;
             2019 will be included.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Symptoms in the first outpatient visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Corporació Sanitària Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 7, 2021</study_first_submitted>
  <study_first_submitted_qc>March 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2021</study_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Corporacion Parc Tauli</investigator_affiliation>
    <investigator_full_name>Anna Selva</investigator_full_name>
    <investigator_title>Clinical Epidemiology and Cancer Screening, Corporació Sanitària Parc Taulí, Sabadell, Spain</investigator_title>
  </responsible_party>
  <keyword>inflammatory bowel disease</keyword>
  <keyword>epidemiology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

